print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
19/11/2012 (Added to site)
Author(s): Mandel, Y.; Rubinsky, B.

Treatment of Uveal Melanoma by Nonthermal Irreversible Electroporation: Electrical and Bioheat Finite Element Model of the Human Eye

Journal: Journal of Heat Transfer - Transactions of the ASME
DOI: 10.1115/1.4005203
Request reprint  |  Tell your friend  | 

Abstract: Nonthermal irreversible electroporation (NTIRE) is an new minimally invasive tissue ablation modality that uses high electric field pulses to produce irreversible permeation of the cell membrane (irreversible electroporation) while avoiding thermal damage and is applied to treat malignant tumors. This paper describes efforts to develop NTIRE as a new minimally invasive treatment modality for uveal melanoma, the most common primary intraocular malignancy in adults, and other ocular malignancies. The paper deals with a 3D mathematical simulation model of the eye that employs the simultaneous solution to the electric field equation and to the Pennes bioheat equation to predict the electric field in the eye as well as the rise in eye temperature in response to the application of a high power electric pulse. Treatment efficacy was defined as the fraction of tumor volume in which the electric field exceeded a predefined target field and treatment safety was calculated by the ratio of the electric field in the tumor to the electric field in the vitreous humor or in the macula. Results show that treatment efficacy and safety are criteria that can be used to optimize the NTIRE treatment protocol.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: